Mary Kay Ash Foundation / Komen / Multiple Mission Foundations

Mary Kay Ash Foundation / Komen / Multiple Mission Foundations

Funds mission-driven founders in health, technology, and social enterprises through philanthropic grant-like programs targeting impact.

Multiple US-based disease-focused private foundations fund biomedical and translational research oriented toward specific disease areas, including neglected tropical diseases, infectious diseases, and cancer. Among the organisations active in this space are the Bill & Melinda Gates Foundation, which funds neglected tropical disease research and global health interventions broadly; the END Fund, which focuses specifically on ending neglected tropical diseases; DNDi (Drugs for Neglected Diseases initiative), which funds the development of new treatments for diseases disproportionately affecting low-income populations; and mission-specific foundations such as Susan G. Komen, which funds breast cancer research. Award sizes across this landscape vary considerably, typically ranging from $25,000 to $2 million depending on the program and foundation, with many awards structured as project grants at the $100,000 to $500,000 level.

Eligibility requirements and geographic scope differ by organisation. The Gates Foundation and Wellcome Trust operate global grant programs spanning basic research through translational and implementation science. Mission-specific cancer foundations generally restrict funding to projects directly aligned with their disease focus. Applicants across this funding landscape can include for-profit biotech and medtech companies, universities, and research organisations; individual applicants are typically ineligible. Technology readiness from early pre-clinical stages through mid-stage translational development (broadly TRL 2 through TRL 7) falls within scope for various programs.

Award instruments vary by funder and program, and may include traditional non-dilutive grants, royalty-bearing arrangements, or milestone-linked funding structures. Applicants should identify the specific foundation or program most aligned with their disease area and research stage, then engage that organisation's application process directly. Given the heterogeneity of this funding cluster, programme terms, deadlines, and eligibility requirements differ substantially across constituent funders, and any single application must be tailored to a specific organisation's stated priorities.